Core Points - The equity change is due to Hainan Yuexin Pharmaceutical Investment Partnership's (Yuexin Pharmaceutical) reduction plan, which does not trigger a mandatory takeover [2][4] - After the equity change, Yuexin Pharmaceutical holds 20,490,100 shares, representing 4.999997% of the total share capital, and is no longer a shareholder with over 5% ownership [2][3] - The equity change will not affect the company's controlling shareholder or actual controller [2][4] Summary of Equity Change - The equity change is in line with the previously disclosed reduction plan and does not trigger a mandatory takeover [4] - The reduction does not involve the company's controlling shareholder or actual controller, ensuring no change in control or governance structure [4] - The company has fulfilled its information disclosure obligations regarding this equity change as per relevant regulations [4]

证券代码：603439 证券简称：贵州三力 公告编号：2025-053 贵州三力制药股份有限公司 关于持股 5%以上股东减持至 5%以下的权益变动提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 通合伙） 流通股 注：以上数据相加不一致的，因四舍五入造成。 公司于 2025 年 9 月 26 日收到股东悦欣医药发来的《简式权益变动报告书》， 悦欣医药于 2025 年 9 月 24 日至 2025 年 9 月 25 日通过集中竞价方式减持 509,900 股，本次权益变动后，悦欣医药持有公司股份 20,490,100 股，占公司总股本的比 例为 4.999997%，不再是公司持股 5%以上的股东。现将有关权益变动的具体情 况公告如下： | 信息披露 | 名称 | 海南悦欣医药投资合伙企业（普通合伙） | | | | | --- | --- | --- | --- | --- | --- | | 义务人基 | | | | | | | 本信息 | 公司住所 | 海南省洋浦经济开发区*** | | | | | ...

贵州三力制药股份有限公司 简式权益变动报告书 信息披露义务人：海南悦欣医药投资合伙企业（普通合伙） 注册地址：海南省洋浦经济开发区*** 通讯地址：海南省洋浦经济开发区*** 股份变动性质：持股比例减少 股票上市地点：上海证券交易所 签署日期：二零二五年九月二十五日 股票简称：贵州三力 1 股票代码：603439 上市公司名称：贵州三力制药股份有限公司 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购管理办法》"）《公开发行证券 的公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"《准 则 15 号》"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》的规定，本报告书已全面披露了信息 披露义务人在贵州三力制药股份有限公司中拥有权益的股份变动情况。截至本报 告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过任何其他方 式增加或减少其在贵州三力制药股份 ...

Core Viewpoint - Guizhou Sanli (603439.SH) announced a significant change in shareholder structure due to the reduction of shares held by Yexin Pharmaceutical, which now holds just under 5% of the company’s total shares [1] Summary by Category Shareholder Changes - Yexin Pharmaceutical reduced its holdings by 509,900 shares from September 24 to September 25, 2025 [1] - Following this transaction, Yexin Pharmaceutical now holds 20,490,100 shares, representing 4.999997% of the total share capital of Guizhou Sanli [1] - Yexin Pharmaceutical is no longer classified as a shareholder with more than 5% ownership in the company [1]

Core Viewpoint - Hainan Yuexin Pharmaceutical Investment Partnership plans to reduce its stake in Guizhou Sanli by selling 509,900 shares, representing 0.12% of the company's total equity [1] Summary by Relevant Sections - **Shareholding Changes** - After the reduction, Hainan Yuexin will hold 20,490,100 shares, which is 5.00% of Guizhou Sanli's total equity [1] - The share reduction is scheduled to occur between September 24 and September 25, 2025 [1] - **Future Intentions** - Hainan Yuexin does not rule out the possibility of further reducing its stake in Guizhou Sanli within the next 12 months [1] - The company has committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations [1]

Core Viewpoint - Guizhou Sanli (603439.SH) announced a significant change in shareholder structure due to the reduction of shares held by Yexin Pharmaceutical, which now holds just under 5% of the company [1] Group 1 - Yexin Pharmaceutical reduced its holdings by 509,900 shares between September 24 and September 25, 2025 [1] - Following this transaction, Yexin Pharmaceutical now owns 20,490,100 shares, representing 4.999997% of the total share capital of Guizhou Sanli [1] - Yexin Pharmaceutical is no longer classified as a shareholder with more than 5% ownership in the company [1]

Group 1 - Guizhou Sanli announced the implementation of its first share buyback on September 20, 2024 [1] - The buyback period will end on September 12, 2025, during which the company has repurchased a total of 7,869,300 shares [1] - The repurchased shares account for 1.92% of the company's total share capital [1]

Group 1 - The company Guizhou Sanli announced the completion of its share repurchase program, having repurchased 7,869,300 shares, which accounts for 1.92% of its total share capital [1] - The repurchase was conducted through centralized bidding, with a maximum transaction price of RMB 14.20 per share, a minimum price of RMB 11.82 per share, and an average price of RMB 12.70 per share [1] - The total amount spent on the repurchase was RMB 99,954,426.00, excluding transaction fees, and the repurchase complies with relevant laws and regulations [1] Group 2 - For the year 2024, Guizhou Sanli's revenue composition is heavily weighted towards the pharmaceutical manufacturing sector, which accounts for 99.97% of its total revenue, while other businesses contribute only 0.03% [1] - As of the report date, Guizhou Sanli has a market capitalization of RMB 5.3 billion [1]

Core Viewpoint - Guizhou Sanli (603439.SH) has completed its share repurchase program, which was set to expire on September 12, 2025, in compliance with relevant laws and regulations [1] Summary by Categories Share Repurchase Details - The company repurchased a total of 7.8693 million shares, representing 1.92% of its total share capital [1] - The highest transaction price during the repurchase was RMB 14.20 per share, while the lowest was RMB 11.82 per share [1] - The average repurchase price was RMB 12.70 per share, with a total expenditure of RMB 99.9544 million (excluding transaction fees) [1]

证券代码：603439 证券简称：贵州三力 公告编号：2025-052 贵州三力制药股份有限公司 | 回购方案首次披露日 | 2024/9/13 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 13 9 月 | 9 | 日~2025 | 年 | 12 | 日 | | 预计回购金额 | 8,000.00万元~12,000.00万元 | | | | | | | 回购价格上限 | 14.20元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 786.93万股 | | | | | | | 实际回购股数占总股本比例 | 1.92% | | | | | | | 实际回购金额 | 9,995.44万元 | | | | | | | 实际回购价格区间 | 11.82元/股~14.20元/股 | | | | | | 一、回 ...